Lumexa Connect: The New Name for a Platform Bet on Outpatient Imaging

A landmark HSS JV and a site-neutrality catalyst frame a Q2 of strategic progress

LMRI · Earnings Call · 2026-08-12

A Strategic Pivot Takes a Name

Lumexa Imaging's second-quarter call was more than a routine earnings update—it was the unveiling of a strategic identity. The company formally christened its operating platform Lumexa Connect, a name that encapsulates how the firm plans to scale across its fragmented industry. As CEO Caitlin Zulla put it, “Lumexa Connect is the operating platform that connects patients, referring physicians, radiologists and health system partners across the imaging journey.” — Caitlin Zulla, Chief Executive Officer · 2026-08-12 This isn't a new product, but a rebranding of a capital-light, best-of-breed approach that the company believes will accelerate its de novo ramp and integration of emerging technologies like virtual MRI and AI-driven dictation. The timing is telling. The stock is still recovering from a -58% drawdown that bottomed in early 2026, but the most recent 90-day trend shows a +56% rebound, suggesting investors are starting to give management credit for the turn. The Q2 results—revenue up 5.1%, adjusted EBITDA of $56.4M, and record free cash flow—provide tangible evidence that the strategy is working, even as the company absorbs public-company costs and de novo investments.

A Landmark Partnership and a Policy Tailwind

The quarter's centerpiece was the joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health. This is Lumexa's ninth health-system JV, and it validates the company's approach of partnering with prestigious institutions to expand outpatient imaging access. Zulla emphasized the significance: “We are honored that HSS chose to partner with Lumexa.” — Caitlin Zulla, Chief Executive Officer · 2026-08-12 The partnership targets the New York metro area, one of the largest healthcare markets in the country, and is expected to be a major growth driver in 2027 and beyond. But the real catalyst for the market is policy. CMS released its 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule in July, which includes site-neutral provisions that would reduce the reimbursement advantage of hospital outpatient departments. For Lumexa, which operates independently of hospital-based reimbursement premiums, this is a structural tailwind. Zulla framed it as a multiyear opportunity:

If finalized as proposed, the site-neutral provisions would reduce the reimbursement advantage associated with hospital outpatient departments and further strengthen the rationale for health systems to expand lower-cost freestanding imaging capacity.
Caitlin Zulla, Chief Executive Officer · 2026-08-12

This is a company-specific inflection point, not just industry boilerplate. While other imaging providers might see the rule as a threat, Lumexa's model is built for it. The company's focus on advanced modalities—which now represent 37.4% of volumes, a record high—positions it to capture the shift to outpatient care.

Execution and the Road Ahead

Operationally, the quarter showed solid execution. Advanced modality volumes grew 6.3% system-wide, with PET up 23.2% (and two new PET machines already live in July). The company also launched a lung cancer screening initiative and is expanding its breast arterial calcification program. CFO Tony Martin highlighted the financial discipline: “Underlying performance benefited from healthy overall volumes and strong growth in advanced modalities, while our reported growth absorbed incremental public company costs and planned investments associated with ramping our de novo centers.” — J. Martin, Chief Financial Officer · 2026-08-12 The guidance was narrowed but maintained at the midpoint, with adjusted EBITDA of $235–$241M and revenue of $1.045B–$1.097B. Free cash flow conversion is expected to be 25–30% of adjusted EBITDA, up from a record 41% in Q2. This follows a series of prior quarters where management repeatedly stressed the seasonality of the business. As Tony said in the prior May call, “We expect about 55% of our adjusted EBITDA to be in the second half of the year.” — J. Martin, Chief Financial Officer · 2026-05-13 That trajectory is on track, with Q1 at 21.5% and Q2 at 23.5%. The company's focus on advanced imaging is not new—it's been a consistent theme. But the naming of Lumexa Connect and the HSS deal signal a more deliberate, platform-driven strategy. Combined with the OPPS catalyst, the second half of 2026 looks set to be a proving ground. As Zulla noted in the April call, “We remain focused on continuing the growth of our advanced imaging.” — Caitlin Zulla, Chief Executive Officer · 2026-04-02 The market is finally starting to listen.